HC Wainwright Predicts argenex’s Q2 Earnings (NASDAQ:ARGX)

argenex SE (NASDAQ:ARGX) – Analysts at HC Wainwright lowered their Q2 2027 earnings per share estimates for argenex in a note issued to investors on Friday, October 23rd. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of $7.83 for the quarter, down from their previous forecast of $8.41. HC Wainwright currently has a “Buy” rating and a $1,202.00 price target on the stock. The consensus estimate for argenex’s current full-year earnings is $26.10 per share. HC Wainwright also issued estimates for argenex’s Q3 2027 earnings at $9.39 EPS and Q4 2027 earnings at $9.76 EPS.

Several other analysts also recently weighed in on ARGX. Truist Financial lifted their target price on shares of argenex from $1,030.00 to $1,095.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Jefferies Financial Group reissued a “buy” rating on shares of argenex in a report on Monday, September 14th. Guggenheim cut their price target on shares of argenex from $1,185.00 to $1,120.00 and set a “buy” rating for the company in a report on Friday, October 23rd. UBS Group raised argenex from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $960.00 to $1,400.00 in a report on Wednesday, August 26th. Finally, Royal Bank Of Canada lowered their price objective on argenex from $1,100.00 to $1,025.00 and set an “outperform” rating on the stock in a report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,145.00.

argenex Stock Performance

Shares of argenex stock opened at $882.48 on Monday. argenex has a one year low of $661.85 and a one year high of $1,072.75. The firm has a fifty day moving average of $951.24 and a two-hundred day moving average of $853.30.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, beating analysts’ consensus estimates of $7.44 by $0.36. The firm had revenue of $1.75 billion during the quarter.

Hedge Funds Weigh In On argenex

A number of large investors have recently made changes to their positions in the stock. Whipplewood Advisors LLC acquired a new stake in shares of argenex in the first quarter valued at about $28,000. Eastern Bank purchased a new stake in shares of argenex during the 2nd quarter worth approximately $32,000. Axiom Investment Management LLC purchased a new stake in shares of argenex during the 1st quarter worth approximately $50,000. WPG Advisers LLC grew its holdings in shares of argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after acquiring an additional 13 shares during the period. Finally, Mather Group LLC. increased its stake in argenex by 19.1% in the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock valued at $78,000 after purchasing an additional 13 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Citigroup lowered its price target to $1,232 from $1,301 but maintained a Buy rating. The revised target still implies substantial upside from the recent trading level, signaling continued confidence in argenx’s growth outlook. Citigroup price-target update
• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $27.76 from $26.27 and increased its Q4 2026 estimate to $7.13 from $6.93. The firm reiterated its Buy rating and $1,202 price objective. HC Wainwright earnings estimates
• Neutral Sentiment: Reported short interest was zero shares as of October 26, producing a 0.0-day short-interest ratio. While this suggests little disclosed short-selling pressure, the figure provides limited insight into near-term trading direction. argenx short-interest report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of argenx investors. The announcement could weigh on sentiment by raising the prospect of litigation, although it did not disclose specific findings or allegations. Pomerantz investor investigation
• Negative Sentiment: HC Wainwright reduced its Q1 2027 EPS forecast to $6.54 from $7.57 and cut its FY2027 estimate to $33.52 from $34.82. These reductions indicate softer longer-term earnings expectations, despite the firm’s continued Buy rating. HC Wainwright earnings estimate changes

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.